pacman schreef op 17 januari 2021 11:50:
Misschien speelt dit ook nog mee nu alles een beetje langer duurt, uit 2015,
Pharming is already working with the Shanghai Institute for Pharmaceutical Industry (SIPI)
However, the first step we are taking as partners is a complete technology transfer to develop Ruconest production in China. This means we are transferring the technology necessary to carry out the entire production process from rabbits to the final dosage form in Shanghai, under FDA and EMA compliant conditions. This will give Pharming a secondary supply chain and lower our cost-of-goods significantly. SIPI will comeercialise Ruconest in China and will pay us four percent royalties on sales. In addition SIPI has agreed to supply us with the purified form of Ruconest on a cost-plus basis, instead of on a full commercial basis as with our current arrangement with our European manaufacturing partners..